Stemline Therapeutics, Inc.
|
|
- George Walker
- 5 years ago
- Views:
Transcription
1 Stemline Therapeutics, Inc. NASDAQ: STML Corporate Presentation January 2018
2 Forward-Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms believes, potentially, estimates, anticipates, expects, plans, intends, may, could, might, will, should, approximately or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. They appear in a number of places throughout this presentation and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations. You should read carefully our Special Cautionary Notice Regarding Forward-Looking Statements and the factors described in the Risk Factors sections of our reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business. 2
3 Investment Highlights Goal is to become a leading commercial stage biotechnology company CD123-targeting represents multi-billion dollar market opportunity BLA submission and possible approval in first CD123 + indication this year Clinical activity in second and third CD123+ indications Pursuing additional indications, including all-comer CD123 trial BPDCN Universe Hematologic Cancers Solid Cancers Autoimmune Abbreviations: BPDCN = blastic plasmacytoid dendritic cell neoplasm 3
4 Clinical Programs
5 Stemline Clinical Programs Additional Clinical Candidates Lead Clinical Program SL-401 Targeted therapy directed to IL-3R (CD123) Breakthrough Therapy Designation (BTD) Pivotal trial in BPDCN met primary endpoint Ramping up pre-launch activities SL-801 XPO-1 inhibitor Phase 1 trial in advanced solid tumors Dose escalation ongoing 5 SL-701 Immunotherapy Phase 2 trial completed in 2nd-line GBM Patient follow-up ongoing
6 Stemline Clinical Pipeline Program Target Indication IND Phase 1 Phase 2 BPDCN SL-401 single agent (Pivotal) Enrollment completed 1 MPN (CMML and MF) SL-401 single agent Enrolling SL-401 IL-3R (CD123) AML (in CR, MRD+) Myeloma (r/r) SL-401 single agent SL pomalidomide + dex Enrolling Enrolling High risk MDS, Elderly AML SL azacitidine Enrolling (IST) SL-801 XPO1 Advanced solid tumors SL-801 single agent Enrolling SL-701 IL-13Ra2 EphA2 Survivin GBM (second-line) SL-701 single agent and + bevacizumab Completed BPDCN = blastic plasmacytoid dendritic cell neoplasm; MPN = myleoproliferative neoplasms; CMML = chronic myelomonocytic leukemia; MF = myelofibrosis; AML = acute myeloid leukemia; CR = complete response; MRD = minimal residual disease; r/r = relapsed/refractory; MDS = myelodysplastic syndrome; IST = investigatorsponsored trial; GBM = glioblastoma multiforme 1 Stage 3 enrollment completed. To ensure continued patient access, Stemline is enrolling first-line and r/r BPDCN patients under the current protocol (Stage 4). 6
7 SL-401: BPDCN
8 BPDCN Overview BPDCN Skin Lesions Background Nomenclature Highly aggressive hematologic malignancy Poor prognosis; median overall survival (OS) 8-14 months Named BPDCN by WHO in Derived from plasmacytoid dendritic cell (pdc) Previous names (prior to 2008) included: - Blastic NK cell leukemia/lymphoma - Agranular CD4+/56+ hematodermic neoplasm Diagnostic Signature Presentation Unmet Medical Need CD123 / CD4 / CD56 and other markers (TCL-1, CD303) Primary sites: bone marrow and skin Secondary sites: lymph nodes, viscera No approved therapies or standard of care Stem cell transplant (SCT) promising for select patients in remission BPDCN Bone Marrow H&E Riaz et al. Cancer Control, 2014; Pagano et al. Haematologica, 2013; Pemmaraju. Curr Hematol Malig Rep, 2017; Bueno et al., Haematologica 2004; Wang et al. Haematologica CD4 CD56 TCL1 CD123
9 SL-401 Pivotal Trial Results
10 Study Design and Inclusion / Exclusion ASH 17 Stage 1 (Lead-in, dose escalation) BPDCN (1L and R/R) ǂ SL-401 (7, 9, 12, or 16 µg/kg) via IV infusion, days 1-5 of a 21- day cycle Key objectives: determine optimal dose and regimen for Stage 2 Stage 2 (Expansion) BPDCN (1L and R/R) SL-401 (12 µg/kg) via IV infusion, days 1-5 of a 21-day cycle Key objectives: further define safety and efficacy BPDCN (1L) Stage 3 (Pivotal, confirmatory) SL-401 (12 µg/kg) via IV infusion, days 1-5 of a 21-day cycle Key objectives: efficacy confirmation for registration Select inclusion criteria Patient Population: - Stage 1: BPDCN (1L or R/R) - Stage 2: BPDCN (1L or R/R) - Stage 3: BPDCN (1L) Age 18; ECOG PS 0-2 Adequate organ function including: LVEF lower limit of normal, creatinine 1.5mg/dL, albumin 3.2 g/dl, bilirubin 1.5 mg/dl, AST/ALT 2.5x ULN Select exclusion criteria Persistent clinically significant toxicities from prior chemotherapy Received chemotherapy or other investigational therapy within the prior 14 days Clinically significant cardiopulmonary disease Receiving immunosuppressive therapy To ensure ongoing access to SL-401, BPDCN patients are being enrolled in an additional cohort, Stage 4 ǂ Stage 1 also enrolled AML (R/R) patients, to be reported separately In BPDCN, 12 µg/kg/day was highest tested dose (MTD not reached) and selected for Stage 2 Abbreviations: 1L = first-line; R/R = relapsed/refractory; IV = intravenous; ECOG PS = Eastern Cooperative Oncology Group performance status; LVEF = left ventricular ejection fraction; ULN = upper limit of normal; MTD = maximum tolerated dose 10
11 Clinical Activity Stage 3 ASH 17 Stage 3: BPDCN (12 µg/kg/day) (n=13 patients) Stage 3 was designed to serve as the pivotal, confirmatory cohort for the SL-401 trial in BPDCN Stage 3 met its primary endpoint with a 54% rate of CR + CRc (7/13) [95% CI: 25.1, 80.8] - The lower bound of the 95% CI exceeded the pre-specified rate of 10% Stage 3 responders ɸ Line of Therapy First-line Dose Level 12 µg/kg n 13 ORR, n (%) 10 (77%) CR + CRc + CRi, n (%) 7 (54%) CR 3 CRc 4 CRi 0 PR, n (%) 3 (23%) Bridged to SCT, n (%) 6 (46%) Allo 6 Auto 0 Stage 3 complete responders ɸ Age (years) Best Response Bone Marrow (% Blasts) Baseline Best response Baseline Skin (mswat) Best response SCT RFS (months) 69 CR 94% 2% 1.2% 0.0% Allo CRc 70% 2% 72.0% 0.0% Allo CR 66% 2% 35.0% 0.0% Allo CRc 22% 1% 54.0% 4.0% CR 12% 1% 70.0% 0.0% Allo CRc 2% 2% 18.0% 0.3% Allo CRc 1% 1% 22.0% 0.4% Allo ɸ As of September 25, Investigator-assessed. ɣ In addition, in Stage 1 (lead-in, dose escalation), 3 BPDCN patients received SL-401 at 7µg/kg/day, of which there was 1 CR and 1 PR: ORR: 67% (2/3), CR + CRc + CRi rate = 33% (1/3). Abbreviations: ORR = overall response rate; CR = complete response; CRc (clinical CR) = absence of gross disease in non-skin organs with gross reduction in cutaneous lesions and residual microscopic skin disease; CRi = CR with incomplete hematologic recovery; CI = confidence interval; PR = partial response; SCT = stem cell transplant; Allo = allogeneic; Auto = autologous; mswat = modified Severity-Weighted Assessment Tool; RFS = relapse free survival. 11
12 Clinical Activity (Stages 1, 2, and 3) ASH 17 Stages 1, 2, and 3 responders ɸ,ɣ Stages 1, 2, and 3: BPDCN (12 µg/kg/day) (n=42 patients) Line of Therapy 1L R/R 1L & R/R n ORR, n (%) 26 (90%) 9 (69%) 35 (83%) CR + CRc + CRi, n (%) 21 (72%) 5 (38%) 26 (62%) CR CRc CRi PR, n (%) 5 (17%) 4 (31%) 9 (21%) Bridged to SCT, n (%) 13 (45%) 1 (8%) 14 (33%) Allo Auto ɸ As of September 25, Investigator-assessed. ɣ In addition, in Stage 1 (lead-in, dose escalation), 3 BPDCN patients received SL-401 at 7µg/kg/day, of which there was 1 CR and 1 PR: ORR: 67% (2/3), CR + CRc + CRi rate = 33% (1/3). Abbreviations: ORR = overall response rate; CR = complete response; CRc (clinical CR) = absence of gross disease in non-skin organs with gross reduction in cutaneous lesions and residual microscopic skin disease; CRi = CR with incomplete hematologic recovery; CI = confidence interval; PR = partial response; SCT = stem cell transplant; Allo = allogeneic; Auto = autologous; mswat = modified Severity-Weighted Assessment Tool; RFS = relapse free survival. 12
13 Safety and Tolerability ASH 17 All SL-401 Clinical Trials (12 µg/kg/day) (n=114 patients) Preferred Term Most Common Adverse Events (AEs) (>15% treatment-related AEs, TRAEs) ƾ All Grades n (%) TRAEs n (%) TRAEs All AEs Grade 1-2 Grade 3 Grade 4 Grade 5 Hypoalbuminaemia 56 (49%) 62 (54%) 55 (48%) 1 (1%) 0 (0%) 0 (0%) Alanine aminotransferase increased 55 (48%) 65 (57%) 25 (22%) 30 (26%) 0 (0%) 0 (0%) Aspartate aminotransferase increased 55 (48%) 63 (55%) 24 (21%) 27 (24%) 4 (4%) 0 (0%) Thrombocytopenia Ж 33 (29%) 42 (37%) 7 (6%) 6 (5%) 20 (18%) 0 (0%) Nausea 31 (27%) 58 (51%) 31 (27%) 0 (0%) 0 (0%) 0 (0%) Pyrexia 29 (25%) 49 (43%) 29 (25%) 0 (0%) 0 (0%) 0 (0%) Chills 26 (23%) 38 (33%) 25 (22%) 1 (1%) 0 (0%) 0 (0%) Fatigue 26 (23%) 57 (50%) 22 (19%) 4 (4%) 0 (0%) 0 (0%) Capillary leak syndrome (CLS) ђ 23 (20%) 23 (20%) 15 (13%) 5 (4%) 2 (2%) 1 (1%) Weight increased 22 (19%) 33 (29%) 22 (19%) 0 (0%) 0 (0%) 0 (0%) Hypotension 20 (18%) 33 (29%) 17 (15%) 3 (3%) 0 (0%) 0 (0%) Oedema peripheral 19 (17%) 50 (44%) 18 (16%) 1 (1%) 0 (0%) 0 (0%) Vomiting 17 (15%) 30 (26%) 17 (15%) 0 (0%) 0 (0%) 0 (0%) ƾ As of October 18, Ж Includes low platelets and platelets decreased. ђ An additional grade 5 CLS-related event occurred in one Stage 4 BPDCN patient (of 11 enrolled) which, in addition to two previously reported grade 5 CLS-related events that occurred at 7 µg/kg/day (BPDCN) and 16 µg/kg/day (AML), reflects a rate of 2.6% (4/153) for all trials and doses, and a rate of 1.7% (2/119) for all trials at the 12 µg/kg/day dose as of
14 Bone Marrow Responses ASH 17 14
15 Best Response and Treatment Duration ASH 17 Stages 1 and 2: First-line BPDCN (12 µg/kg/day) Stage 3: First-line BPDCN (12 µg/kg/day) Individual patients CR CR CRc CR PR CR CR CR CRc CR CRi CRc PR CRi CR CR Allo Auto Auto Allo Allo Allo u SL-401 Stem cell transplant (SCT) Receiving SL-401, ongoing Auto u CRc CR CR CR CRc CRc CRc PR PR SD SD PR Allo Allo Allo Allo Allo Allo SL-401 Stem cell transplant (SCT) Exited study in remission Time (Months) As of September 25, Investigator-assessed Time (Months) As of September 25, Investigator-assessed. Patient relapsed off study at 7.3 months.
16 Overall Survival (OS) ASH 17 First-line BPDCN (12 µg/kg/day) Stage 1 and 2 OS (from first dose) Stage 3 OS (from first dose) 16
17 SL-401: BPDCN Market Opportunity
18 SL-401: Multiple Opportunities for Growth within BPDCN Universe BPDCN (EU) BPDCN Signature Maintenance Therapy (post-sct) BPDCN (US) 18
19 SL-401: Multiple Opportunities for Growth within BPDCN Universe BPDCN (EU) BPDCN Signature Maintenance Therapy (post-sct) BPDCN (US) ~40% first-line BPDCN patients on SL-401 bridged to SCT Study Design In Process 19
20 SL-401: Multiple Opportunities for Growth within BPDCN Universe BPDCN Signature (30%) x (16%) x new AML cases (EHA, 2016) Potential upside 20
21 SL-401: Multiple Opportunities for Growth within BPDCN Universe BPDCN (EU) BPDCN Signature Similar patient size to US Filing Discussions Underway Maintenance Therapy (post-sct) (30%) x (16%) x new AML cases (EHA, 2016) Potential upside BPDCN (US) ~40% first-line BPDCN patients on SL-401 bridged to SCT Study Design In Process 21
22 BPDCN Awareness Highlighting Utility of CD123 Testing 22
23 SL-401: Market Expansion Opportunities
24 SL-401: Additional Opportunities SL-401 across multiple indications Both single agent and in combination; various administration schedules MPN (CMML, MF) AML in CR, MRD + Multiple myeloma (r/r) High risk MDS or elderly AML unfit for chemo Regimen SL-401 SL-401 SL Pomalidomide* SL Azacytidine* Lead-in (Stage 1) Completed Completed Enrolling Enrolling Expansion (Stage 2) Enrolling Enrolling Not started yet Not started yet Dose and Schedule 12 ug/kg/day (3 days every 3-4 wks) 12 ug/kg/day (5 days every 4 wks) Optimal dose and schedule TBD Optimal dose and schedule TBD Efficacy readout ORR CR rate MRD decrease DFS pdc decrease ORR CR rate *Preclinical data support combination (synergy or potentiation) 24
25 SL-401: Additional Opportunities SL-401 across multiple indications Both single agent and in combination; various administration schedules MPN (CMML, MF) AML in CR, MRD + Multiple myeloma (r/r) High risk MDS or elderly AML unfit for chemo Regimen SL-401 SL-401 SL Pomalidomide* SL Azacytidine* Lead-in (Stage 1) Completed Completed Enrolling Enrolling Expansion (Stage 2) Enrolling Enrolling Not started yet Not started yet Dose and Schedule 12 ug/kg/day (3 days every 3-4 wks) 12 ug/kg/day (5 days every 4 wks) Optimal dose and schedule TBD Optimal dose and schedule TBD Efficacy readout ORR CR rate MRD decrease DFS pdc decrease ORR CR rate *Preclinical data support combination (synergy or potentiation) 25
26 SL-401: Results from Ongoing Phase 1/2 Trial in Myeloproliferative Neoplasms Including CMML and MF
27 SL-401 MPN Phase 1/2 Trial ASH 17 Study Design Demographics Safety and Tolerability Stage 1 Lead-in (Completed) MPN: CMML, MF, SM, and PED SL-401 (7, 9, or 12 µg/kg) via IV infusion, days 1-3 of a 21-day cycle (cycles 1-4), a 28-day cycle (cycles 5-7); a 42-day cycle thereafter Key objectives: determine optimal dose and regimen for Stage 2 Stage 2 Expansion ( Enrolling) MPN: CMML or MF without evidence of transformation SL-401 (12 µg/kg) via IV infusion, days 1-3 of a 21-day cycle (cycles 1-4), a 28-day cycle (cycles 5-7); a 42-day cycle thereafter Key objectives: further define safety and efficacy Age, years n = 24 Median [range] 69 [43 81] Gender Male 13 (54) MPN MF 12 (50) CMML-1 7 (29) CMML-2 4 (17) SM 1 (4) Median ECOG Median ECOG [range] 1 [0-2] Median Blast Count, % Median [range] 5 [0-15] Prior lines of treatment [n, (%)] Prior SCT 3 (12) JAKi 9 (38) HMA 7 (29) Baseline sites of disease [n, (%)] BM 13 (63) Spleen 17 (75) Liver 5 (21) Enrollment by Stage (dose) Stage 1 (7, 9, 12 µg/kg) 9 (3, 3, 3) Stage 2 (12 µg/kg) Most Common Adverse Events ( 15% of treatment related adverse effects, TRAEs) Preferred Term All Grades n (%) TRAEs n (%) TRAEs All AEs G1 & 2 G3 G4 G5 Hypoalbuminemia 7 (33.3) 8 (38.1) 7 (33.3) Thrombocytopenia 7 (33.3) 8 (38.1) 2 (9.5) 4 (19.0) 1 (4.8) -- Fatigue 6 (28.6) 11 (52.4) 5 (23.8) 1 (4.8) Alanine aminotransferase increased 5 (23.8) 6 (28.6) 4 (19.0) 1 (4.8) Anemia 5 (23.8) 10 (47.6) 1 (4.8) 4 (19.0) Capillary leak syndrome (CLS) 5 (23.8) 5 (23.8) 4 (19.0) 1 (4.8) Oedema peripheral 5 (23.8) 13 (61.9) 5 (23.8) Nausea 4 (19.0) 10 (47.6) 4 (19.0) Vomiting 4 (19.0) 8 (38.1) 4 (19.0) As of October 25, Detailed Safety assessments on three patients are pending Includes low platelets and platelets decreased
28 SL-401 MPN Trial: Best Spleen Response ASH 17 Splenomegaly (cm palpable below left costal margin) Patient Dose Received (µg/kg) Histology Overall Best Response Screening Best Response Percent Change Time to response (weeks) 6 9 CMML-1 CR % CMML % CMML-2 SD % MF SD % MF % MF SD % CMML % CMML % MF SD % CMML % MF SD % CMML % 7.9 Stage 1 Stage 2 Abbreviations: CR = Complete response; SD = Stable disease 28
29 MPN: Best Response, Treatment Duration / Summary and Next Steps ASH 17 SL-401 Trial in MPN (CMML and MF) Safety No DLTs or MTD identified. Most common TRAEs include hypoalbuminemia (33%), thrombocytopenia (33%), and fatigue (29%). Most common TRAEs, grade 3+, include thrombocytopenia (24%) and anemia (19%) Efficacy Durable CR (14+ months) noted in CMML patient 65% (11/17 evaluable) CMML and MF patients had spleen reductions >25% (range 29% to 100%) Durable SD in 4 patients (2 CMML, 2 MF) for 5+ to 8+ months, 3 ongoing All 3 ongoing patients had baseline platelet counts <100,000, including 1 patient platelet count <50,000 Next Steps Continue enrollment and patient follow-up Favorable tolerability and preliminary signs of activity support both single agent and combination development strategies, including JAK-inhibitors and hypomethylating agents 29
30 Key Accomplishments and Upcoming Milestone Events 2017 Timing Program Expected Event 1Q17 SL-401 Completed enrollment of BPDCN pivotal trial 2Q17 SL-401 Clinical update in BPDCN at EHA 2H17 SL-401 Top-line pivotal data ASH 17 SL-401 Detailed pivotal data ASH 17 SL-401 Updates on additional indications 2018 Timing Program Expected Event 1H18 SL-401 BLA submission Mid-18 SL-401 Commercial build-out, hire salesforce 2H18 SL-401 EMA pre-filing meeting 2H18 SL-401 Potential US approval 2H18 SL-401 Formulate registration strategy for additional indication(s) 2H18 SL-401 Updates on ongoing and new clinical trials 30
31 SL-801
32 SL-801: Overview SL-801 Novel, oral, small molecule inhibitor of XPO1 (Exportin 1) XPO-1 Target Key nuclear transport oncogene Over-expressed by variety of solid and liquid cancers Clinically-validated target in multiple cancer types SL-801: Novel and Differentiated Novel molecular structure Reversibly inhibits XPO1 Potential for safety and therapeutic window benefit Phase 1 Trial Patients with advanced solid tumors Data presented at ESMO 2017 Dose escalation; enrollment ongoing 32
33 SL-801: Rationale XPO1 inhibition may be a promising therapeutic strategy in certain KRAS-mutant cancers 33
34 SL-801: Study Design Stage 1 (Dose-escalation) - Enrollment Ongoing Advanced solid tumors SL-801 orally administered - Dose escalation (mg/day) o 5, 10, 20, 30, and by 5 mg increments thereafter - D1-4 and D8-11 of a 21-day cycle - Standard 3x3 design Endpoints - Safety and tolerability - DLT and MTD - ORR, DCR, DoR, PFS and OS Six sites in the US Stage 2 (Expansion) - Not started yet Disease-specific cohorts (up to 4 cohorts) - ~20 patients per cohort SL-801 orally administered - Dose and regimen to be selected from Stage 1 Endpoints - ORR - Safety profile - CR, DoR, PFS, OS Ø Signal detection for subsequent registration-directed Phase 2 trials DLT = dose-limiting toxicity; ORR = overall response rate; DCR = disease control rate; DoR = duration of response; PFS = progression-free survival; OS = overall survival; MTD = maximum tolerated dose; CR = complete response 34
35 SL-801: Patient demographics (n=24) ESMO 17 Age, years Median [range] 64 [39-76] Gender [n, (%)] Male 13 (54) Lines of therapy prior to the study [n, (%)] 1 st Line 1 (4) 2 nd Line 5 (22) 3 rd Line 18 (74) KRAS mutation [n, (%)] Yes 4 (16.6) No 7 (29) Unknown 13 (54) ECOG performance status [n, (%)] 0 6 (25) 1 17 (71) 2 1 (4) Follow-up time on study, months Median [range] 1.4 [ ] Cancer Diagnosis n Colorectal cancer (CRC) 5 Breast cancer 3 Non-small cell lung cancer (NSCLC) 2 GI adenocarcinoma (GI Adeno) 2 Pancreatic cancer 2 Neuroendocrine (Neuro-endo) 2 Biliary 1 Renal 1 Bladder 1 Ovarian carcinoma 1 Basal cell carcinoma (BCC) 1 Small bowel 1 Mesothelioma (Mesoth) 1 Anal squamous cell carcinoma (SCC) 1 *As of 31-Jul Investigator-assessed data; unaudited. 35
36 SL-801: Safety and Tolerability ESMO 17 Treatment Related Adverse events (AEs) (n= 24 patients) Most Common Treatment Related Adverse Events ( 15%) All Grades n (%) TRAEs n (%) Preferred Term TRAEs All AEs G1 & 2 G3 G4 G5 Nausea 10 (41.7) 14 (58.3) 9 (37.5) 1 (4.2) No DLT s reported No MTD Dose escalation ongoing Ø Enrolling 8 th cohort (50 mg/day) Fatigue 7 (29.2) 10 (41.7) 7 (29.2) Diarrhea 5 (20.9) 8 (33.3) 4 (16.7) 1 (4.2) Vomiting 4 (16.7) 10 (41.7) 4 (16.7) Decreased appetite 4 (16.7) 7 (29.2) 4 (16.7) *As of 31-Jul Investigator-assessed data; unaudited. There was also one grade 3 TRAE of acute kidney injury reported at 30 mg/day dose level 36
37 SL-801: Clinical Activity ESMO 17 Sum of target lesions (measurable) Dose Tumor Histology No. of lesions Screening (mm) Best Response (mm) % Δ of target lesions Overall response assessment Time to Best Response Last dose received Remains on Therapy 30 mg Neuro-endo % SD C2 C6D1 No 30 mg GI Adeno % SD C4 C7D1 No 40 mg BCC % SD C2 C3D11 Yes 40 mg Breast % SD C2 C2D1 Yes 5 mg CRC % SD C2 C6D1 No 10 mg Anal SCC SD C2 C4D1 No 40 mg Mesoth % SD C2 C2D1 No 20 mg Breast % SD C2 C2D1 No *As of 31-Jul Investigator-assessed data; unaudited. (-) = reduction; (+) = increase; SD = stable disease 1 Patient with KRAS mutation present at screening An additional patient (cholangiocarcoma), not shown, sustained SD on SL-801 (35mg cohort); data on tumor size pending 37
38 SL-801: Trial Status and Next Steps Next Steps Dose escalation continues - 8 th cohort (50 mg/day) currently enrolling Further efficacy and safety updates expected 2018 Additional trials planned include single agent, combination, and hematologic cancers 38
39 SL-701
40 SL-701: Background SL-701 is an off-the-shelf, systemically-delivered (subcutaneous) immunotherapy Short synthetic peptides, some mutated, to generate antigen specific CD8 + T cell response - Co-administered with immunostimulants Targets (IL-13Ra2, Ephrin A2, Survivin) over-expressed on glioblastoma (GBM) GBM targets: Mechanism of Action Directs T cells to GBM IL-13Ra2 IL-13Ra2, Survivin, Ephrin A2 Overexpression of SL-701 targets on GBM Normal brain GBM T cell response/inflammation in brain biopsy post-systemic therapy (earlier version of SL-701) Abundant CD8 + T cells Survivin EphA2 Adapted from Uematsu, MJ. Neurooncol, 2005 and Wykosky, J. Clin Cancer Res, 2008 Numerous CD68 + macrophages JCO, 2011; ASCO,
41 SL-701: Treatment Related Adverse Events ( 5%) (n=74) SNO 17 Preferred Term All Grades n (%) TRAEs n (%) TRAEs All AEs Grade 3 Fatigue 16 (21.6) 29 (39.2) 2 (2.7) 1 Injection site reaction 13 (17.6) 15 (20.3) -- Injection site erythema 9 (12.2) 11 (14.9) -- Injection site pain 8 (10.8) 9 (12.2) -- Injection site induration 6 (8.1) 8 (17.4) -- Headache 6 (8.1) 24 (32.4) -- Nausea 5 (6.8) 15 (20.3) -- Injection site swelling 5 (6.8) 4 (8.7) -- Skin induration 5 (6.8) 3 (6.5) -- Chills 4 (5.4) 3 (6.5) -- 1 Both cases were Grade 3 41
42 SL-701: Disease Control and Duration of Response SNO 17 Disease Control, Including Major Responses Stage 1 Stage 2 n (evaluable/total) 46/46 28/28 Disease control 1, n (rate; DCR) 16 (35%) 27 (96%) Overall response, n (rate; ORR) 1 (2%) 6 (21%) Complete response (CR), n (rate) 0 (0%) 2 (7%) Partial Response (PR), n (rate) 1 (2%) 4 (14%) Stable Disease (SD), n (rate) 15 (33%) 21 (75%) Major responses and durable stable diseases in 2nd-line GBM As both a single agent and in combination with bevacizumab Stage 1: Duration of Response or 6 Mo SD months (n=46) Stage 2: Duration of Response or 6 Mo SD months (n=28) 1 Disease control = CR + PR + SD 42
43 SL-701: Overall Survival (OS) SNO 17 Stage 1 (n=46) Stage 2 (n=28) OS-12: 36% Median OS = 10.9 months OS-12: 48% Median OS = 11.7 months OS-12 = Overall Survival at 12 months 43
44 SL-701: Clinical Benefit and Robust Immune Response SNO 17 Patient Narrative 60 year-old male Grade IV GBM, KPS 90%, MGMT promoter methylated, non-mutated IDH1 Prior treatment: 1 resections + Stupp + Veliparib Received SL bevacizumab - CR after 4 months - Confirmed by 2 nd assessment Target-specific CD8+ T cells CR Pre-SL months of SL months of SL months of SL
45 SL-701: Conclusions and Next Steps Major responses and durable stable diseases with SL-701 alone and in combination with bevacizumab in second-line GBM Well-tolerated, very manageable side effect profile Long-term survivors with SL-701 alone (Stage 1) and in combination with bevacizumab (Stage 2), including ~48% 12-month OS survival probability in Stage 2 Robust target-specific CD8 + T-cell responses in patients experiencing clinical benefit consistent with mechanism of action Given the major unmet medical need in GBM and promising safety and efficacy data generated to date with SL-701, Stemline is considering next steps including possible registration-directed trial designs 45
46 Upcoming Milestones
47 Key Accomplishments and Upcoming Milestone Events Timing Program Expected Event 1Q17 SL-401 Completed enrollment of BPDCN pivotal trial 2Q17 SL-401 Clinical update in BPDCN at EHA ESMO 17 SL-801 Phase 1 update 2H17 SL-401 Top-line pivotal data SNO 17 SL-701 Patient follow-up update ASH 17 SL-401 Detailed pivotal data ASH 17 SL-401 Updates on additional indications Timing Program Expected Event 1H18 SL-401 BLA submission Mid-18 SL-401 Commercial build-out, hire salesforce 2H18 SL-401 EMA pre-filing meeting 2H18 SL-401 Potential US approval 2H18 SL-401 Formulate registration strategy for additional indication(s) 2H18 SL-801 Further trial and program updates 2H18 SL-701 Further program updates 2H18 SL-401 Updates on ongoing and new clinical trials 47
48 Financial Summary
49 Financial Summary As of September 30, 2017 Cash, Cash Equivalents and Investments (MM) $79.9 Debt $0.0 Shares Outstanding (MM) ~
50 Stemline Therapeutics, Inc. NASDAQ: STML Corporate Presentation January 2018
Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. NASDAQ: STML Jefferies 2016 Healthcare Conference June 8, 2016 Forward-Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements.
More informationStemline Therapeutics, Inc.
Stemline Therapeutics, Inc. NASDAQ: STML Corporate Presentation March 2016 Forward-Looking Statements This presentation includes statements that are, or may be deemed, forwardlooking statements. In some
More informationStemline Therapeutics, Inc.
Stemline Therapeutics, Inc. NASDAQ: STML Corporate Presentation August 2018 2 Forward-Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In
More informationTARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018
NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements
More informationDana-Farber Cancer Institute, Boston, MA; 2 City of Hope National Medical Center, Duarte, CA; 3 Roswell Park Cancer Institute, Buffalo, NY; 4
Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD) Andrew A.
More informationNewLink Genetics Corporation
Cantor Fitzgerald 2018 Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK October 3, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking
More informationCorporate Overview. May 2017 NASDAQ: CYTR
Corporate Overview May 2017 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationSummary of Key AML Abstracts Presented at the American Society of Hematology (ASH) December 2-6, San Diego CA
Summary of Key AML Abstracts Presented at the American Society of Hematology (ASH) December 2-6, 2016 - San Diego CA ASH 2016 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://ash.confex.com/ash/2016/webprogram/start.html
More information[ NASDAQ: MEIP ] Analyst & Investor Event December 8, 2014
[ NASDAQ: MEIP ] Analyst & Investor Event December 8, 2014 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results may
More informationStemline Therapeutics, Inc.
Stemline Therapeutics, Inc. NAAQ: STML Corporate Presentation October 08 ForwardLooking Statements This presentation includes statements that are, or may be deemed, forwardlooking statements. In some cases,
More informationTransforming science into medicine
Transforming science into medicine 2 Forward-looking statements This presentation contains forward-looking statements. These statements include words like may, expects, believes, plans, scheduled, and
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationCelyad s CAR-T NKR-2 Program. Conference Call Presentation Wednesday, December 7 th :00pm CET / 8:00am EST
Celyad s CAR-T NKR-2 Program Conference Call Presentation Wednesday, December 7 th 2016 2:00pm CET / 8:00am EST Forward Looking Statements In addition to historical facts or statements of current condition,
More informationSummary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain
Summary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain EHA 2017 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://learningcenter.ehaweb.org/eha/#!*listing=3*browseby=2*sortby=1*media=3*ce_id=1181*label=15531
More informationCorporate Overview. July 2016 NASDAQ: CYTR
Corporate Overview July 2016 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES ASSOCIATED WITH A DEVELOPMENT-STAGE
More informationNewLink Genetics Corporation
Stifel Healthcare Conference Presentation NewLink Genetics Corporation NASDAQ: NLNK November 13, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements
More informationCorporate Presentation
Corporate Presentation Leerink Global Healthcare Conference February 14 th -15 th, 2018 C O N F I D E N T I A L a n d P R O P R I E T A R Y Forward Looking Statements / Safe Harbor This presentation contains
More informationDisclosure. Study was sponsored by Karyopharm Therapeutics No financial relationships to disclose Other disclosures:
Combination of Selinexor with High-Dose Cytarabine and Mitoxantrone for Remission Induction in Acute Myeloid Leukemia is Feasible and Tolerable A Phase I Study (NCT02573363) Amy Y. Wang, Howie Weiner,
More informationPhase I Study of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multicenter MMRC Clinical Trial
Phase I Study of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multicenter MMRC Clinical Trial Jonathan L. Kaufman, Todd Zimmerman, Cara A. Rosenbaum, Anuj Mahindra,
More informationInducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy
Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Company Overview, September 2018 Safe Harbor Statement This presentation contains forward-looking
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationUse of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories
Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion
More informationIMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationASCO Analyst & Investor Webcast. June 1, 2018
ASCO Analyst & Investor Webcast June 1, 2018 June 1, 2018 NASDAQ: BLUE Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information
More informationREWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES
REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES May 18, 2017 Molecularly Defined Solid Tumor Program Update FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations,
More informationKaryopharm Reports Second Quarter 2015 Financial Results and Highlights Recent Progress
August 10, 2015 Karyopharm Reports Second Quarter 2015 Financial Results and Highlights Recent Progress - Positive Selinexor Clinical Data Presented across Several Difficult to Treat Cancers - - Provides
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outline Molecular biology Chemotherapy and Hypomethylating agent Novel Therapy
More informationSafety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia
Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia Abstract 102 Wei AH, Strickland SA, Roboz GJ, Hou J-Z, Fiedler W, Lin TL,
More informationForward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, including statements related to Seattle Genetics corporate priorities, financial guidance and anticipated upcoming activities,
More informationEnasidenib Monotherapy is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 Acute Myeloid Leukemia
Enasidenib Monotherapy is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 Acute Myeloid Leukemia Pollyea DA 1, Tallman MS 2,3, de Botton S 4,5, DiNardo CD 6, Kantarjian HM
More informationBuilding a Fully Integrated Biopharmaceutical Company. June 2014
Building a Fully Integrated Biopharmaceutical Company June 2014 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation
More information[ NASDAQ: MEIP ] Wedbush PacGrow Healthcare Conference August 16-17, 2016
[ NASDAQ: MEIP ] Wedbush PacGrow Healthcare Conference August 16-17, 2016 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events
More informationBuilding a Leading Oncology Franchise
ASDAQ: MEIP Building a Leading Oncology Franchise 17th Annual eedham Healthcare Conference March 27, 2018 Forward-Looking Statements This presentation contains, and our officers and representatives may
More informationInvestor Call. May 19, Nasdaq: IMGN
Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not
More informationBio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia
Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia Interim Data Update from Phase 2 Study Demonstrates Meaningful Clinical Improvement with
More information[ NASDAQ: MEIP ] Cowen and Company Health Care Conference March 2015
[ NASDAQ: MEIP ] Cowen and Company Health Care Conference March 2015 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or
More informationTwo-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS
Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome Two-stage study designed to evaluate tolerability
More informationBackground CPX-351. Lancet J, et al. J Clin Oncol. 2017;35(suppl): Abstract 7035.
Overall Survival (OS) With Versus in Older Adults With Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (taml): Subgroup Analysis of a Phase 3 Study Abstract 7035 Lancet JE, Rizzieri D, Schiller
More informationClinical: Ipilimumab (MDX-010) Update and Next Steps
Clinical: Ipilimumab (MDX-010) Update and Next Steps Geoffrey M. Nichol, M.D., M.B.A. Senior Vice President, Product Development Medarex, Inc. R&D Day December 9, 2005 Ipilimumab: New Class of Cancer Therapy
More informationActinium Pharmaceuticals, Inc.
, Inc. Actimab-A MRD Consolidation Strategy in MRD+ AML July 10, 2018 1 Disclaimer and Safe Harbor Some of the information presented herein may contain projections or other forward-looking statements regarding
More informationDisrupting the Cell Cycle to Treat AML and MDS Rodman & Renshaw Conference
CYC 682 Disrupting the Cell Cycle to Treat AML and MDS Rodman & Renshaw Conference September 2014 Disclaimer This presentation contains forward-looking statements within the meaning of the safe harbor
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More information[ NASDAQ: MEIP ] Cantor Fitzgerald Healthcare Conference July 8, 2015
[ NASDAQ: MEIP ] Cantor Fitzgerald Healthcare Conference July 8, 2015 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or
More informationCompany Overview. April Rewriting cancer treatment NASDAQ: EPZM
Company Overview NASDAQ: EPZM Rewriting cancer treatment Forward Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationPersonalized Therapy for Acute Myeloid Leukemia. Patrick Stiff MD Loyola University Medical Center
Personalized Therapy for Acute Myeloid Leukemia Patrick Stiff MD Loyola University Medical Center 708-327-3216 Major groups of Mutations in AML Targets for AML: Is this Achievable? Chronic Myeloid Leukemia:
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking
More informationNASDAQ: TGTX Jefferies Healthcare Conference June 2015
NASDAQ: TGTX Jefferies Healthcare Conference June 2015 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationGenta Incorporated. A Multiproduct Late-Stage Oncology Company
Genta Incorporated A Multiproduct Late-Stage Oncology Company This presentation may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking
More informationCorporate Presentation
Corporate Presentation June 2017 Forward-Looking Statements This presentation contains forward-looking statements reflecting management s current beliefs and expectations. These forward looking statements
More informationA Biopharmaceutical Company Focused on Controlled Immunotherapies and Point-of-Care Solutions
A Biopharmaceutical Company Focused on Controlled Immunotherapies and Point-of-Care Solutions Second Quarter 2017 Company Update and Financial Results July 31, 2017 2 Forward-Looking Statements This presentation
More informationMyelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data
Instructions for Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data (Form 2114) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Myelodysplasia/Myeloproliferative
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationCorporate Overview. June 2018 NASDAQ:FPRX
Corporate Overview June 2018 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
More informationVAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may
More informationNational Bank 8th Annual Quebec Conference TSX: IMV. May 30, IMV Inc. All rights reserved.
National Bank 8th Annual Quebec Conference TSX: IMV May 30, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV Inc.
More informationANCO: ASCO Highlights 2018 Hematologic Malignancies
ANCO: ASCO Highlights 2018 Hematologic Malignancies Brian A. Jonas, M.D., Ph.D. UC Davis Comprehensive Cancer Center August 25, 2018 Brian Jonas, MD, PhD ANCO: ASCO Highlights 2018 Relevant financial relationships
More informationMANIFEST Phase 2 Enhancement / Expansion
MANIFEST Phase 2 Enhancement / Expansion Investor Conference Call Stellar Science, Breakthrough Medicine October 11, 2018 Forward-Looking Statements This presentation contains forward-looking statements
More informationCompany Overview. January 2019
Company Overview January 2019 1 Disclaimer This Presentation includes certain projections and forward-looking statements as of the date of this Presentation provided by Gamida Cell Ltd (the Company ).
More informationJefferies 2018 Healthcare Conference. June 6, 2018
Jefferies 2018 Healthcare Conference z June 6, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the timing of the start and conclusion of ongoing
More informationFull Year 2017 Financial Results. February 14, 2018
Full Year 2017 Financial Results February 14, 2018 Agios Conference Call Participants Prepared Remarks Introduction KENDRA ADAMS, Sr. Director, Investor Relations 2018 Vision & Key Milestones DAVID SCHENKEIN,
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationNASDAQ: TGTX. 33 rd Annual JP Morgan Healthcare Conference
NASDAQ: TGTX 33 rd Annual JP Morgan Healthcare Conference January 2015 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities
More informationQuarterly Update & ASH 2017 Abstract Conference Call
Quarterly Update & ASH 2017 Abstract Conference Call November 1, 2017 Nasdaq : BLUE 1 Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More informationBuilding a Leading Oncology Franchise
Building a Leading Oncology Franchise January 2019 NASDAQ: MEIP Forward-Looking Statements This presentation contains, and our officers and representatives may from time to time make, statements that are
More informationPrevious Study Return to List Next Study
A service of the U.S. National Institutes of Health Trial record 1 of 1 for: ASP 2215-cl-0101 Previous Study Return to List Next Study Dose Escalation Study Inv e stigating the Safe ty, Tole rability,
More informationARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc. June 8, 2016 David Sachs Non-small cell lung cancer 1 ARIAD clinical trial patient Some of the statements in this presentation constitute forward looking statements under the
More informationCorporate Presentation June Curis, Inc All Rights Reserved
Corporate Presentation June 2018 Curis, Inc. 2018 All Rights Reserved Forward Looking Statements This presentation contains certain forward-looking statements about Curis, Inc. ( we, us, or the Company
More informationThird Quarter 2018 Financial Results. November 1, 2018
Third Quarter 2018 Financial Results November 1, 2018 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Associate Director, Investor Relations Business Highlights & 2018 Key
More informationCompany presentation. Claudio Bordignon, Chairman and CEO. Jefferies Global Healthcare Conference New York, 7 June 2012
Company presentation Claudio Bordignon, Chairman and CEO Jefferies Global Healthcare Conference New York, 7 June 2012 Forward-looking statements The presentation contains certain forward-looking statements.
More informationMyeloid Differentiation Observed, Including Induction of CD38 in 85% of Evaluable Patients
December 10, 2017 Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients Clinical
More informationFirst Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented
More informationStifel Healthcare Conference John Scarlett, M.D. Chief Executive Officer November 19, 2014
Stifel Healthcare Conference 2014 John Scarlett, M.D. Chief Executive Officer November 19, 2014 1 forward-looking statements Except for statements of historical fact, the statements during this presentation
More informationBuilding Shareholder Value
Building Shareholder Value June 4, 2014 Jefferies Healthcare Conference Tim Clackson, Ph.D. Hans Loland P r e s i d e n t o f R & D, C h i e f S c i e n t i f i c O f f i c e r with wife Cynthia A R I
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationNewLink Genetics Corporation
Cantor Fitzgerald Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK September 25, 2017 Forward-Looking Disclaimer This presentation contains forward-looking statements of NewLink that
More informationBR is an established treatment regimen for CLL in the front-line and R/R settings
Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory CLL: Results of a phase III randomized double-blind placebo-controlled study Andrew D. Zelenetz,
More informationAbstract 861. Stein AS, Topp MS, Kantarjian H, Gökbuget N, Bargou R, Litzow M, Rambaldi A, Ribera J-M, Zhang A, Zimmerman Z, Forman SJ
Treatment with Anti-CD19 BiTE Blinatumomab in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation Abstract
More informationCorporate Presentation
Corporate Presentation October 2018 NASDAQ/TSX: TRIL This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking
More informationActinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting
December 4, 2018 Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting - Key highlights include near universal engraftment
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationNY-ESO SPEAR T-cells in Synovial Sarcoma
NY-ESO SPEAR T-cells in Synovial Sarcoma ASCO Update June 6, 2017 Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform
More informationCARs vs. BiTE in ALL. David L Porter, MD Jodi Fisher Horowitz Professor University of Pennsylvania Health System Abramson Cancer Center
CARs vs. BiTE in ALL David L Porter, MD Jodi Fisher Horowitz Professor University of Pennsylvania Health System Abramson Cancer Center Disclosure Information David L Porter Speaker and members of study
More informationAsterias Biotherapeutics NYSE American: AST
Clinical-Stage Cell Therapy Programs Addressing Significant Unmet Medical Needs in Neurology and Oncology Asterias Biotherapeutics NYSE American: AST November 2017 Forward-Looking Statements Statements
More informationCONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS
CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS December 2017 Christine K. Gause, Ph.D Executive Director, Biostatistics. 2 Microsatellite Instability-High Cancer - USPI KEYTRUDA is indicated
More informationCautionary Note Regarding Forward-Looking Statements
lndoximod Combined with Standard Induction Chemotherapy Is Well Tolerated and Induces a High Rate of Complete Remission with MRD-Negativity in Patients with Newly Diagnosed AML: Results from a Phase 1
More informationDicerna Pharmaceuticals Overview. Delivering RNAi-Based Breakthrough Therapies
Pharmaceuticals Overview Delivering RNAi-Based Breakthrough Therapies Forward-Looking Statements This information may contain projections and other forward looking statements regarding future events, including
More informationBusiness Update & Financial Results for Q1 2018
Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More informationDisclosure Slide. Research Support: Onconova Therapeutics, Celgene
Oral Rigosertib Combined with Azacitidine in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS): Effects in Treatment Naïve and Relapsed- Refractory Patients Shyamala C. Navada,
More informationCorporate Overview May 8, 2014
0 Corporate Overview May 8, 2014 NASDAQ: CRIS Forward Looking Statements This presentation contains statements about Curis future expectations, plans and prospects that constitute forward-looking statements
More informationASH POSTER: LYMRIT UPDATE
ASH POSTER: LYMRIT 37-01 UPDATE DECEMBER 2018 EDUARDO BRAVO, CEO LISA ROJKJAER, MD, CMO Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway www.nordicnanovector.com IR contact: ir@nordicnanovector.com
More informationPharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765
Contact: Ramses Erdtmann Vice President of Finance Phone: 408-215-3325 Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765 Company to Host
More informationProteasome inhibitor (PI) and immunomodulatory drug (IMiD) refractory multiple myeloma is associated with inferior patient outcomes
Alliance A061202. A phase I/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor
More information